Pune: The Serum Institute of India (SII) is currently developing another vaccine with US drug-maker Novavax. Serum’s CEO Adar Poonawalla said on Saturday he hopes to launch the new vaccine ‘Covovax’ by June.
Covovax has been found to be 89.3 per cent effective in a UK trial.
“Our partnership for a COVID-19 vaccine with @Novavax has also published excellent efficacy results. We have also applied to start trials in India. Hope to launch #COVOVAX by June 2021!” Poonawalla tweeted this afternoon.
Poonawalla’s firm is already making Covishield, developed in partnership with the Oxford University and British-Swedish firm AstraZeneca. Covishield and Bharat Biotech’s Covaxin are being used in the first phase of vaccination process in India.
Also Read: Serum Institute Of India Applies For Study Trial Of Novavax Vaccine
